Hospital Universitario de Salamanca
Hospital Universitario de Salamanca
Salamanca, Spain29 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Follow-up in Gynecological Cancer Survivors | female reproductive organ cancer | Active, not recruiting | Not stated | 2026-10-07 | NCT03515993 | |
| A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, bone marrow disorder, hematologic disorder, primary myelofibrosis | Recruiting | Phase 1 / Phase 2 | 2026-10-02 | NCT04176198 | |
| A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) | Cytopenia, Hemic and Lymphatic Diseases, bone marrow disorder, hematologic disorder, myelodysplastic syndrome | Recruiting | Phase 2 | 2026-08-21 | NCT04419649 | |
| A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT | DNA Virus Infections, Infections, adenoviridae infectious disease, viral infectious disease | Recruiting | Phase 3 | 2026-08-10 | NCT07387367 | |
| Abbott Medical - VERITAS Study | Arrhythmias, Cardiac, Pathologic Processes, Pathological Conditions, Signs and Symptoms, atrial fibrillation, cardiovascular disorder, heart disorder | Active, not recruiting | Not applicable | 2026-08-04 | NCT06707688 | |
| Single Dose Double-blind, Placebo-controlled Cross-over (SDDBPCCO) Shiftability Study, Will be Followed by a 10-week Open-label Study With Arbaclofen (4 Weeks of Titration and Then 6 Weeks of Active/Stable Treatment). The Effects of Arbaclofen on Target EEG and ERG Metrics Will be Associated With th | autism spectrum disorder, neurodevelopmental disorder, pervasive developmental disorder, psychiatric disorder | Recruiting | Phase 3 | 2026-06-17 | NCT07655115 | |
| A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 3 | 2026-05-22 | NCT04628494 | |
| A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Phase 2 | 2026-05-11 | NCT06384261 | |
| Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma | High-Risk de Novo Multiple Myeloma | Active, not recruiting | Phase 2 | 2026-05-11 | NCT05849610 | |
| Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 1 / Phase 2 | 2026-05-11 | NCT05060627 | |
| Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients. | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 2 | 2026-05-08 | NCT05527340 | |
| A Precision Medicine Trial for Patients With Relapsed or Refractory T Cell ALL | LAL | Not yet recruiting | Phase 2 | 2026-04-17 | NCT07522801 | |
| A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) | Blood Protein Disorders, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Recurrence, acute myeloid leukemia, bone marrow disorder, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, monoclonal gammopathy, myelodysplastic syndrome, myeloid leukemia, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 / Phase 2 | 2026-03-24 | NCT04988555 | |
| A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 3 | 2026-03-17 | NCT05257083 | |
| Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Not applicable | 2026-02-20 | NCT06446882 | |
| Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, estrogen-receptor positive breast cancer, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-02-12 | NCT02947685 | |
| PARADIGM: Amplatzer Valvular Plug for PVL Closure | Paravalvular Aortic Regurgitation | Active, not recruiting | Not applicable | 2026-02-10 | NCT04489823 | |
| A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis | Cytopenia, Hemic and Lymphatic Diseases, Myeloproliferative Disorders, anemia, blood platelet disease, bone marrow disorder, hematologic disorder, primary myelofibrosis, thrombocytopenia | Recruiting | Phase 2 | 2026-02-05 | NCT05037760 | |
| Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms. | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, acute myeloid leukemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Phase 1 | 2026-01-20 | NCT06359002 | |
| Urinary Biomarker-Based Diagnostic and Monitoring System for Chronic Kidney Disease and Real-World Effectiveness of SGLT2 Inhibitors | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, chronic renal failure syndrome, kidney disorder, kidney failure, urinary system disorder | Not yet recruiting | Not stated | 2026-01-16 | NCT07348484 | |
| SyncAV Post-Market Trial | cardiovascular disorder, congestive heart failure, heart disorder, heart failure | Active, not recruiting | Not applicable | 2025-12-18 | NCT04100148 | |
| A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 3 | 2025-12-04 | NCT05028348 | |
| REmote iSchemic condItioning in Lymphoma PatIents REceiving ANthraCyclinEs | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Not applicable | 2025-09-18 | NCT05223413 | |
| Long-Term Follow-up Study of Early Stage Breast Cancer Patients Included in GEICAM Studies | Invasive Breast Cancer Early Stages | Recruiting | Not stated | 2025-05-14 | NCT03390894 | |
| Innoventric Trillium™ Stent Graft First-in-Human (FIH) Study | cardiovascular disorder, heart disorder, heart valve disorder, tricuspid valve insufficiency | Active, not recruiting | Not applicable | 2025-03-07 | NCT04289870 |